NCT06139406View on ClinicalTrials.gov

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

November 19, 2027

Study Completion Date

November 19, 2027

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

JNJ-87801493

JNJ-87801493 will be administered subcutaneously.

DRUG

JNJ-80948543

JNJ-80948543 will be administered subcutaneously.

DRUG

JNJ-75348780

JNJ-75348780 will be administered subcutaneously.

Trial Locations (12)

2031

RECRUITING

Scientia Clinical Research, Randwick

3004

RECRUITING

The Alfred Hospital, Melbourne

3084

COMPLETED

Austin Hospital, Heidelberg

5000

RECRUITING

Odense University Hospital, Odense

6009

RECRUITING

Linear Clinical Research Ltd, Nedlands

28040

ACTIVE_NOT_RECRUITING

Hosp Univ Fund Jimenez Diaz, Madrid

31008

ACTIVE_NOT_RECRUITING

Clinica Univ. de Navarra, Pamplona

37007

ACTIVE_NOT_RECRUITING

Hosp Clinico Univ de Salamanca, Salamanca

6423906

RECRUITING

Sourasky (Ichilov) Medical Center, Tel Aviv

9112001

RECRUITING

Hadassah Medical Center, Jerusalem

DK-2100

RECRUITING

Rigshospitalet, Copenhagen

08035

ACTIVE_NOT_RECRUITING

Hosp Univ Vall D Hebron, Barcelona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY